This Biopharmaceutical Company Expands Its Out-Licensing Deal For Pancreatic Cancer Patients
Can-Fite BioPharma Expands Out-Licensing Deal with Ewopharma: A New Hope for Pancreatic Cancer Patients.
Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.
In a significant development, Can-Fite BioPharma Ltd. (NYSE: CANF), a biopharmaceutical company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer, and liver diseases, has recently expanded its out-licensing deal with Ewopharma AG, a Swiss-based pharmaceutical company. The expansion now includes the pancreatic cancer indication, marking a substantial step forward in the fight against this deadly disease.
Pancreatic cancer is a particularly aggressive form of the disease, with an alarmingly low five-year survival rate of just 10%. This makes the development of effective treatments all the more urgent, and any progress in this field could potentially save countless lives.
This development holds the potential to revolutionize the pancreatic cancer treatment landscape. The expansion of the out-licensing deal allows both companies to explore the potential of their drug candidates more comprehensively and could lead to a breakthrough in pancreatic cancer treatment.
It is important to note that the expanded agreement is subject to certain terms and conditions, including regulatory approvals for the drug candidates involved. Nonetheless, it represents a beacon of hope for pancreatic cancer patients worldwide.
In conclusion, the expansion of the out-licensing deal between Can-Fite and Ewopharma signifies a crucial step forward in the fight against pancreatic cancer. With the combined expertise and resources of these two pharmaceutical giants, there is renewed hope for effective treatments and improved survival rates for patients diagnosed with this aggressive disease.
As an investor it's important to stay updated with major news. Get real-time stock market alerts and research by creating an account here.
Sources: